SNST (Aphex BioCleanse Systems) Equity-to-Asset: 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aphex BioCleanse Systems Equity-to-Asset?

Aphex BioCleanse Systems SNST Equity-to-Asset is 0.00 as of . 20.

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Aphex BioCleanse Systems's Total Stockholders Equity for the quarter that ended in . 20 was $0.00 Mil. Aphex BioCleanse Systems's Total Assets for the quarter that ended in . 20 was $0.00 Mil.

The historical rank and industry rank for Aphex BioCleanse Systems's Equity-to-Asset or its related term are showing as below:

SNST's Equity-to-Asset is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 0.55
* Ranked among companies with meaningful Equity-to-Asset only.

Aphex BioCleanse Systems  (OTCPK:SNST) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Aphex BioCleanse Systems Equity-to-Asset Related Terms

Aphex BioCleanse Systems Equity-to-Asset Historical Data

* Premium members only.

The historical data trend for Aphex BioCleanse Systems's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aphex BioCleanse Systems Equity-to-Asset Chart

Aphex BioCleanse Systems Annual Data
Trend
Equity-to-Asset

Aphex BioCleanse Systems Quarterly Data
Equity-to-Asset

Aphex BioCleanse Systems Equity-to-Asset Competitor Comparison

For the Household & Personal Products subindustry, Aphex BioCleanse Systems's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aphex BioCleanse Systems Equity-to-Asset vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Aphex BioCleanse Systems's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Aphex BioCleanse Systems's Equity-to-Asset falls into.


Aphex BioCleanse Systems Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Aphex BioCleanse Systems's Equity to Asset Ratio for the fiscal year that ended in . 20 is calculated as

Equity to Asset (A: . 20 )=Total Stockholders Equity/Total Assets
=/
=

Aphex BioCleanse Systems's Equity to Asset Ratio for the quarter that ended in . 20 is calculated as

Equity to Asset (Q: . 20 )=Total Stockholders Equity/Total Assets
=/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Equity-to-Asset →
What does a Equity-to-Asset of 0.00 mean?
Aphex BioCleanse Systems (SNST) has a Equity-to-Asset of 0.00 as of . 20. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aphex BioCleanse Systems and its competitors.
Is Aphex BioCleanse Systems' Equity-to-Asset too high?
Aphex BioCleanse Systems' current Equity-to-Asset is 0.00.
How does Aphex BioCleanse Systems' Equity-to-Asset compare to competitors?
Aphex BioCleanse Systems' Equity-to-Asset of 0.00 can be compared against companies in the Consumer Packaged Goods industry. The industry median Equity-to-Asset is 0.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Consumer Packaged Goods company?
The median Equity-to-Asset among Consumer Packaged Goods companies is 0.55, based on 1,994 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aphex BioCleanse Systems and its competitors. For the Consumer Packaged Goods industry, the median Equity-to-Asset is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aphex BioCleanse Systems's current Equity-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aphex BioCleanse Systems stock overvalued right now?
Aphex BioCleanse Systems (SNST) has a current Equity-to-Asset of 0.00. The current Equity-to-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Aphex BioCleanse Systems (SNST), the current Equity-to-Asset is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aphex BioCleanse Systems Business Description

Address 1820 State Road 13, Unit 11-43, Saint Johns, FL, USA, 32259
Aphex BioCleanse Systems Inc is a United States-based company that provides sanitization solutions. It develops and manufactures non-alcohol, non-toxic, and hydrogen-based disinfecting technology. The company produces proprietary hydrogen-based disinfectant and pesticide products known as Hy-IQ Water.